Alivus Life Sciences Ltd.

Glenmark Life Sciences has informed that the company at its meeting held on April 20, 2022, has considered and approved: The audited Financial Results for the Year ended March 31, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The copy of the said results together with Management Discussion & Analysis, Press Release, Auditors Report and Declaration of unmodified opinion are enclosed. These are also being made available on the website of the Company at www.glenmarklifesciences.com, Recommended final Dividend of Rs 10.5 per share (face value of Rs 2 each) on the Equity Share Capital of the Company for the financial year 2021 - 22 subject to the approval of the Shareholders at the ensuing Annual General Meeting,  On the recommendations of Nomination and Remuneration Committee and approval of the Audit Committee, Board approved the appointment of Tushar P. Mistry as the Chief Financial Officer (designated as Key Managerial Personnel) of the Company with effect from June 1, 2022 and Bhavesh Pujara has resigned as the Chief Financial Officer of the Company with effect from the close of business hours on April 22, 2022. Consequently, he also ceases to be the Key Managerial Personnel of the Company. The said meeting of the Board commenced at 4.10 pm and concluded at 7.10 pm.

The above information is a part of company’s filings submitted to BSE.